Overview

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Phase:
PHASE1
Details
Lead Sponsor:
SciTech Development, Inc.
Treatments:
Fenretinide
MAC-ST-001